Abstract
Pyrazinamide (PZA) is a common drug that causes serious adverse events (SAEs). The aim of this study was to determine the incidence of and risk factors for SAEs due to PZA during first-line anti-tuberculosis treatment. The medical records of patients with tuberculosis (TB) treated with PZA-containing regimens including first-line drugs-ethambutol, rifampicin, and isoniazid-from January 2003 to June 2016 were reviewed. SAEs were defined as side effects that led to drug discontinuation. The causative drug was determined based on the disappearance of the SAEs upon drug withdrawal and/or the recurrence of the same SAEs with re-challenge. Of 2,478 patients with TB, 16.4% experienced SAEs. The incidence of SAEs increased significantly as age increased, except with rifampin. PZA accounted for most SAEs (55.8%). Hepatotoxicity was the most common SAE due to PZA (44.5%), followed by gastrointestinal (GI) intolerance (23.8%). The risk of SAEs due to PZA increased significantly as age increased, when sex and comorbidities were adjusted (odds ratio, 1.013; 95% confidence interval, 1.004-1.023; P = 0.007). In the subgroup analysis, older age was an independent risk factor for GI intolerance but not for hepatotoxicity. PZA was the most commo...Continue Reading
References
Oct 1, 1996·The European Respiratory Journal·T SchabergH Lode
Feb 6, 2003·American Journal of Respiratory and Critical Care Medicine·Daphne YeeDick Menzies
Apr 12, 2005·Journal of the American Academy of Nurse Practitioners·Maryann M Fulton, Elizabeth Riley Allen
Jul 17, 2007·Lancet·Louise MalletAllen Huang
Apr 1, 2008·Critical Reviews in Oncology/hematology·Jay F PiccirilloEwout W Steyerberg
Apr 5, 2008·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
Sep 30, 2010·Diabetes Care·Solomon TesfayeUNKNOWN Toronto Diabetic Neuropathy Expert Group
Nov 24, 2011·PloS One·Kocfa Chung-DelgadoAntonio Bernabe-Ortiz
Mar 10, 2012·Thorax·Libo LiangLiyuan Han
Jan 30, 2013·Antimicrobial Agents and Chemotherapy·Tung-Yuan ShihOliver Yoa-Pu Hu
Feb 12, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A C PettitJ V Warkentin
Mar 21, 2013·BMC Infectious Diseases·Yong Soo KwonYoung Chul Kim
Jun 8, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·C-C ShuL-N Lee
Jun 12, 2013·PloS One·Xiaozhen LvSiyan Zhan
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Dec 18, 2013·Thorax·Catherine SmithMark Reacher
Feb 6, 2015·Journal of Korean Medical Science·Ina JeongJae-Ho Lee
Mar 1, 2013·Journal of Clinical and Experimental Hepatology·Vidyasagar Ramappa, Guruprasad P Aithal
May 8, 2015·Journal of Laboratory Physicians·Sarman SinghV M Katoch
Apr 9, 2016·Journal of Primary Care & Community Health·Arunava SahaT Balamugesh
Jul 10, 2016·Clinics in Geriatric Medicine·Shobita Rajagopalan
Jul 13, 2016·Infectious Disease Reports·Mario Raviglione, Giorgia Sulis
Aug 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Sep 14, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Mar 16, 2017·The Pan African Medical Journal·Omaima El BouazziRachid Bengueddour
Nov 29, 2017·The Cochrane Database of Systematic Reviews·Francis A MhimbiraDavid Sinclair
Jul 4, 2018·PLoS Medicine·Narges AlipanahPayam Nahid
Jun 24, 2019·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Eri HagiwaraTakashi Ogura